MRK.DE Merck KGaA
Company Analysis
Latest News
🟢 Merck KGaA is trading 4.15% up with no identified company-specific catalyst
Merck KGaA is trading 4.15% higher at €141.70; available reporting does not identify a fresh company-specific announcement explaining the move. - The rise is...
Merck KGaA, Eisai Win FDA Approval for WELIREG-LENVIMA Kidney Cancer Combo
Merck KGaA and Eisai received U.S. Food and Drug Administration (FDA) approval for WELIREG (belzutifan) in combination with LENVIMA (lenvatinib). The treatment...
Merck KGaA Jumps as HSBC Upgrades Stock, Citing Attractive Valuation
Merck KGaA shares rose nearly 1.9% during daily trading. The stock price reached €141.60 following an HSBC rating upgrade. HSBC raised its recommendation on...
Merck KGaA Falls, UBS Flags Generic Competition Risks for Mavenclad
Merck KGaA shares fell 1.45% on Thursday. The stock closed at €136.35, underperforming the German DAX index. UBS downgraded the healthcare and technology...
Merck KGaA Wins German Approval for Bio-Techne Buy, Boosting Life Sciences
Germany’s Federal Cartel Office approved Merck KGaA’s acquisition of Bio-Techne. This regulatory clearance satisfies a primary condition for the transaction to...
Merck KGaA Secures FDA Breakthrough Status for Potential First Lupus Skin Therapy
The FDA granted Breakthrough Therapy Designation to Merck KGaA’s enpatoran for lupus patients with active skin manifestations. This designation accelerates the...